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Eighty-six patients with tumour induced hypercalcaemia were randomised to 600, 900, 1200 or 1500 mg of intravenous
clodronate, according to post hydration serum calcium levels. Sixty-seven were evaluable for response. The overall response
rate was 49.3% (95% CI: 36.8–61.8) with no signiﬁcant difference in response rates, i.e. achievement of normocalcaemia at
days 6–9 (corrected serum calcium 42.6 mmol l
71) across all groups.
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Bisphosphonates are potent inhibitors of osteoclast activity and
have become standard treatment for TIH (Body, 2000). Several
studies have explored dose response relationships for different
bisphosphonates and degree of hypercalcaemia (Body et al, 1987,
1994, 1999; Thiebaud et al, 1988; Nussbaum et al, 1993; Pecher-
storfer et al, 1996; Ralston et al, 1988, 1997). There have been
few studies however exploring this dose response relationship for
single dose clodronate, the majority of which have involved conse-
cutive daily clodronate infusions rather than single dose
comparisons (Adami et al, 1987; Urwin et al, 1987; Bonjour et
al, 1988; Kanis et al, 1990). At this tertiary cancer centre, single
dose clodronate is currently used as ﬁrst line treatment for TIH.
The aim of this study was to evaluate its dose response relationship
in TIH.
METHODS
This was a partially, randomised, non-blinded study, comparing
four doses of intravenous clodronate in patients admitted with
TIH in a tertiary cancer centre. Local research and ethics commit-
tees approved the study protocol. Patients were eligible for the
study if: (1) they were aged over 18 years; (2) had a non-haemato-
logical malignancy; (3) were willing and able to give written
informed consent; and (4) had a corrected serum calcium level
52.6 mmol l
71 after a minimum of 24 h rehydration with at least
2 l of intravenous normal saline. Patients excluded from the study
included those with: (1) previous bisphosphonate treatment for
hypercalcaemia; (2) hypercalcaemia as part of a ‘ﬂare’ reaction to
endocrine therapy; (3) a change in corticosteroid therapy in the
previous 7 days; (4) intolerance of the initial volume load of rehy-
dration; or (5) impaired renal function (serum creatinine 51.5
times the upper limit of normal following rehydration). All demo-
graphic details, evidence of bone metastases and previous
bisphosphonate treatment for bone pain were recorded for all
patients. Calcium values were corrected for albumin using the
formula, (corrected calcium=measured calcium+((40-serum albu-
min)60.02)).
Patients were randomised to receive a single dose of clodro-
nate by intravenous infusion in 500 ml normal saline over 3–
4 h according to post-hydration corrected serum calcium.
Patients with a corrected calcium level of: (1) 2.6–3.0 mmol l
71
were randomised to either 600, 900 or 1200 mg clodronate; (2)
3.0–3.4 mmol l
71 were randomised to 900, 1200 or 1500 mg;
(3) 3.5–3.9 mmol l
71 were randomised to 1200 or 1500 mg;
and (4) 54.0 mmol l
71 were prescribed 1500 mg. Intravenous
ﬂuids were continued, at the discretion of the attending physi-
cian, until the patient was able to drink adequately. Serum
levels of calcium, albumin, urea and electrolytes and liver func-
tion tests were recorded at days 0, 1, 3, 5, 7 and 9. All
biochemical investigations were performed using standard auto-
mated techniques. Patients were continually assessed for adverse
effects. Primary response was deﬁned as achievement of normo-
calcaemia (corrected serum calcium 42.6 mmol l
71) at days 6–
9. Secondary endpoints recorded included the time to relapse
and survival following treatment of hypercalcaemia. Patients fail-
ing to achieve normocalcaemia at days 6–9 were withdrawn
from the study and given further treatment at the discretion
of the physician in charge.
Statistical methods
This study set out to test whether the effect seen in the study by
Thiebaud et al (1988) could be replicated. Randomisation to all
dose groups irrespective of initial serum calcium was not consid-
ered ethical, so the best compromise between an observational
and randomised study was used. The sample size was such that
its power to detect an effect of the same size as that of Thiebaud
would have exceeded 80%. The Mann Whitney test for trend was
used to test whether there was a trend in response rates across
the four dose categories. The mean values presented are geometric
means, i.e. they are back transformed means of the log transformed
values.
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Eighty-six patients were recruited. Nineteen patients were
excluded from analysis because of missing data in seven patients
and death prior to completion of the study (10 patients). One
patient was randomised but later excluded because of renal
impairment; and one patient received chemotherapy after rando-
misation. A total of 67 patients were therefore evaluable for
response. Patients were well matched for age, sex, tumour type,
previous bisphosphonate treatment, and time of presentation
from time of ﬁrst development of bone metastases and hypercal-
caemia (Table 1). Table 2 shows corrected calcium levels and
response rates for the four groups. There were signiﬁcant reduc-
tions in serum calcium with treatment in all four groups. There
was no signiﬁcant difference in response rates across the groups.
The presence or absence of bone metastases (in 55% and 35% of
patients respectively) had no signiﬁcant bearing on response rates
(P=0.14). There was no signiﬁcant difference in response between
those patients with breast (52%), lung (33%) or other malignan-
cies (44%). Equal numbers of patients received further anti-
cancer treatment with either chemotherapy, radiotherapy or
hormonal treatment (mean 57%; range 46–63%). There was
no difference in the median time to relapse nor median survival
after treatment which was only 43 days (range 8 days to 43
years).
DISCUSSION
In this study, there were no statistically signiﬁcant difference in
response rate between varying doses of clodronate. Low dose clodro-
natewasequallyeffectiveintreatingmildTIHashighdoseclodronate
was in treating moderate to severe TIH. Response rates were lower
than that reported by O’Rourke et al (1993) of 80% for 1500 mg
clodronate. This may be because of a relatively high proportion of
patients with humoral hypercalcaemia (Kanis et al, 1990, 1994). Only
54%ofpatients in thisstudywere knowntohave bone metastasesand
all patients with haematological malignancies (including myeloma
and lymphoma) were excluded. O’Rourke et al (1993) found a differ-
ential response rate of only 50% in patients with humoral
hypercalcaemia compared to 74% in patients with bone metastases
and 100% in myeloma patients (one sixth of patients recruited). This
effect has been reported by other studies (Body et al, 1987; Body and
Dumon, 1994; Thiebaud et al, 1988; Ralston et al, 1997). In this study,
no signiﬁcant difference in response rate was seen between tumour
types and patients with or without bone metastases but the number
of patients in each group was small. Another study comparing 300
and 600 mg single infusions of clodronate reported response rates
of only 17% and 40% respectively (Kanis et al, 1990).
In summary, this study conﬁrms that clodronate is a safe and
effective treatment for TIH but failed to conﬁrm the dose response
relationship seen in the study of Thiebaud et al (1988).
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Table 1 Demographic characteristics of patients
P-value
600 mg 900 mg 1200 mg 1500 mg Total
Diagnosis
Breast 9 3 5 2 19
H & N 0 3 104
Lung 1 4 2 2 9
Renal 1 4 5 2 12
Other 4 7 8 4 23
Randomised 18 23 31 14
Evaluable 15 21 21 10
Age
Median (years) 61 57 60 55 ns
Range 37–92 31–77 40–83 34–57
Months after 1st bone metastases 8 0 3.5 0.5 ns
Range 0–59 0–12 0–45 0–2
Number previously treated with bisphosphonates 1 0 1 1 ns
ns=not signiﬁcant. P-value of 50.05 was considered as signiﬁcant.
Table 2 Response to intravenous clodronate
600 mg 900 mg 1200 mg 1500 mg
(n=15) (n=21) (n=21) (n=10) P-value
Mean serum calcium
Day 0 2.87 3.13 3.10 3.27 50.001
(95% CI) (2.78, 2.95) (3.03, 3.23) (3.02, 3.19) (3.05, 3.52)
Days 6–9 2.67 2.62 2.63 2.71
(95% CI) (2.57, 2.78) (2.54, 2.7) (2.54, 2.73) (2.53, 2.91)
P-value 0.005 50.001 50.001 50.001
% Achieving complete response, i.e. Ca 52.6 mmol
71
% 46.7 47.6 57.1 40.0 ns
(95% CI) (21.27, 73.4) (25.71, 70.2) (34.02, 78.2) (12.16, 73.8)
ns=not signiﬁcant. P-value of 50.05 was considered as signiﬁcant.
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